Pharmacotherapy in Children — MCQs
For a child 3-5 months of age with H1N1, treatment Oseltamivir dose is
What is the effect of indomethacin on the ductus arteriosus?
Dosage of a drug in a child is typically calculated based on which of the following parameters?
What agent is used for pupil dilatation in children?
Which vitamin deficiency is most commonly seen in a pregnant mother receiving phenytoin therapy for epilepsy?
Which of the following drugs are known to cause fetal renal anomalies?
Which of the following medications is absolutely contraindicated for a mother who is breastfeeding her newborn baby?
Which parameter is most important for determining drug dosage in a child?
The most common adverse effect particularly seen in young children because of the use of sodium valproate is:
Gray baby syndrome is caused by which of the following drugs?
Pharmacotherapy in Children Indian Medical PG Practice Questions and MCQs
Question 1: For a child 3-5 months of age with H1N1, treatment Oseltamivir dose is
- A. 12 mg BD X 5 days
- B. 25 mg BD X 5 days
- C. 20 mg OD X 5 days
- D. 20 mg BD X 5 days (Correct Answer)
Explanation: ***20 mg BD X 5 days*** - For infants aged **3-5 months** with H1N1 influenza, the recommended dose of **Oseltamivir** is **20 mg twice daily** (BD) for **5 days**. This dosage is based on weight-based recommendations to ensure appropriate antiviral activity. - This treatment regimen is crucial for reducing the severity and duration of influenza symptoms in this vulnerable age group and should be initiated as early as possible. *12 mg BD X 5 days* - This dosage is typically recommended for younger infants, specifically those aged **less than 1 month up to 2 months** (up to 3 kg body weight). - It is **underdosing** for a child in the 3-5 months age range, which could lead to suboptimal antiviral effect. *25 mg BD X 5 days* - This dosage is generally used for children weighing **between 15 kg and 23 kg**, which is significantly higher than the average weight for an infant aged 3-5 months. - Administering this dose to a 3-5 month old would constitute an **overdose**, potentially leading to increased side effects such as nausea, vomiting, or other adverse reactions. *20 mg OD X 5 days* - While 20 mg is the correct single dose, giving it **once daily (OD)** is incorrect for treating H1N1 influenza in infants. - Oseltamivir requires a **twice-daily (BD)** regimen to maintain therapeutic drug levels and effectively inhibit viral replication over the 24-hour period.
Question 2: What is the effect of indomethacin on the ductus arteriosus?
- A. Closure of the ductus in premature neonates (Correct Answer)
- B. Patent ductus arteriosus
- C. Closure of the ductus in term and premature neonates
- D. Closure of the ductus in older children
Explanation: **Explanation:** **Mechanism of Action:** The patency of the ductus arteriosus (DA) in utero is maintained by high levels of circulating **Prostaglandin E2 (PGE2)**, which acts as a potent vasodilator. **Indomethacin** is a non-selective Cyclooxygenase (COX) inhibitor. By inhibiting the COX enzyme, it decreases the synthesis of PGE2, leading to the constriction and subsequent functional **closure of the ductus arteriosus.** **Why Option A is Correct:** Indomethacin is specifically effective in **premature neonates** because their ductal tissue is highly sensitive to prostaglandin levels. In these infants, the ductus often fails to close spontaneously due to hypoxia or immature lungs, and pharmacological intervention can prevent the need for surgical ligation. **Analysis of Incorrect Options:** * **Option B:** This describes the pathology itself. Indomethacin is the *treatment* for Patent Ductus Arteriosus (PDA), not the cause. * **Option C:** Indomethacin is generally **ineffective in term neonates**. In full-term infants, the ductal smooth muscle is more developed and less dependent on prostaglandins for patency; closure is primarily driven by the postnatal rise in oxygen tension. * **Option D:** In older children, the ductus has typically undergone anatomical remodeling (fibrosis into the ligamentum arteriosum) or is too structurally fixed for prostaglandin inhibition to have any effect. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** While Indomethacin was the traditional gold standard, **Ibuprofen (IV)** is now often preferred due to a lower risk of renal toxicity and necrotizing enterocolitis (NEC). * **Alternative:** **Paracetamol (Acetaminophen)** is an emerging alternative for PDA closure with a superior safety profile. * **Opposite Effect:** If a neonate has a cyanotic heart defect (e.g., Transposition of Great Arteries), we want to keep the ductus open. The drug used for this is **Alprostadil (PGE1 analog)**.
Question 3: Dosage of a drug in a child is typically calculated based on which of the following parameters?
- A. Race
- B. Weight (Correct Answer)
- C. Sex
- D. Height
Explanation: **Explanation:** In pediatric pharmacology, drug dosing is not a "one size fits all" approach because children are not merely "small adults." Their physiological processes—including gastric emptying, total body water percentage, and organ maturation—differ significantly. **Why Weight is the Correct Answer:** Body weight (expressed in mg/kg) is the most common and practical parameter used for calculating pediatric dosages. It accounts for the significant variations in size across different pediatric age groups (neonates to adolescents). While **Body Surface Area (BSA)** is technically the most accurate method for drugs with a narrow therapeutic index (like chemotherapy), **weight-based dosing** remains the standard clinical gold standard for most routine medications due to its ease of calculation and reliability. **Why Other Options are Incorrect:** * **Race (A):** While pharmacogenomics can influence drug metabolism (e.g., Isoniazid acetylation), race is never used as a primary parameter for calculating initial pediatric dosages. * **Sex (C):** Hormonal differences between sexes generally do not impact drug dosing until puberty; it is not a standard parameter for pediatric calculations. * **Height (D):** Height alone does not account for body mass or metabolic capacity. It is, however, used as a component to calculate BSA. **High-Yield Clinical Pearls for NEET-PG:** * **Young’s Formula:** $Age / (Age + 12) \times \text{Adult Dose}$ (Used for children > 2 years). * **Dilling’s Formula:** $Age / 20 \times \text{Adult Dose}$ (Easier to calculate, often tested). * **Fried’s Formula:** $Age (\text{in months}) / 150 \times \text{Adult Dose}$ (Used specifically for infants). * **Clark’s Rule:** $Weight (\text{in lbs}) / 150 \times \text{Adult Dose}$ (Based on weight). * **Gold Standard:** BSA-based dosing is superior to weight-based dosing for precision but is more complex to calculate ($BSA = \sqrt{[Height(cm) \times Weight(kg)] / 3600}$).
Question 4: What agent is used for pupil dilatation in children?
- A. Atropine (Correct Answer)
- B. Homatropine
- C. Tropicamide
- D. Phenylephrine
Explanation: **Explanation:** In pediatric ophthalmology, the drug of choice for pupil dilatation and cycloplegic refraction is **Atropine**. **1. Why Atropine is Correct:** Children have very high accommodative power due to a strong ciliary muscle. To perform an accurate refraction (especially to detect latent hypermetropia or accommodative esotropia), complete paralysis of the ciliary muscle (**cycloplegia**) is required. Atropine is the most potent cycloplegic available. It is typically administered as a 1% ointment or drops for 3 days prior to the examination to ensure maximal effect. **2. Why the other options are incorrect:** * **Homatropine:** It is a semi-synthetic derivative of atropine but is significantly less potent. It is rarely used for refraction in children because it may result in incomplete cycloplegia. * **Tropicamide:** While it has the fastest onset and shortest duration (making it the drug of choice for adults), its cycloplegic action is too weak for the strong accommodative reflex of a child. * **Phenylephrine:** This is a sympathomimetic (alpha-1 agonist) that causes mydriasis (dilation) but **no cycloplegia**. It is often used as an adjunct but cannot be used alone for pediatric refraction. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Atropine is the DOC for children <7 years; Cyclopentolate is preferred for children 7–12 years; Tropicamide is preferred for adults. * **Systemic Toxicity:** In children, always apply pressure over the lacrimal sac (punctal occlusion) after instilling drops to prevent systemic absorption, which can cause "Atropine flushing," fever, and tachycardia. * **Contraindication:** Avoid atropine in children with Down Syndrome, as they may show an exaggerated pupillary response and heart rate.
Question 5: Which vitamin deficiency is most commonly seen in a pregnant mother receiving phenytoin therapy for epilepsy?
- A. Vitamin B6
- B. Vitamin B12
- C. Vitamin A
- D. Folic acid (Correct Answer)
Explanation: **Explanation:** **Phenytoin** is a widely used antiepileptic drug known for its specific metabolic side effects, particularly regarding folate metabolism. **Why Folic Acid is the Correct Answer:** Phenytoin causes folic acid deficiency through three primary mechanisms: 1. **Inhibition of Absorption:** It inhibits the enzyme intestinal conjugase, which is required to break down dietary polyglutamates into absorbable monoglutamates. 2. **Enzyme Induction:** As a potent inducer of hepatic CYP450 enzymes, phenytoin increases the demand for folate as a co-factor in drug metabolism. 3. **Antagonism:** It may interfere with the uptake of folate by cells. In pregnant women, this deficiency is critical as it significantly increases the risk of **Neural Tube Defects (NTDs)** and can lead to megaloblastic anemia. **Why Other Options are Incorrect:** * **Vitamin B6 (Pyridoxine):** Deficiency is classically associated with **Isoniazid (INH)** therapy, not phenytoin. * **Vitamin B12:** While B12 deficiency also causes megaloblastic anemia, phenytoin specifically targets folate pathways. B12 deficiency is more common in metformin use or gastric bypass. * **Vitamin A:** Phenytoin does not interfere with the absorption or metabolism of fat-soluble Vitamin A. **High-Yield Clinical Pearls for NEET-PG:** * **Fetal Hydantoin Syndrome:** Characterized by craniofacial anomalies (cleft lip/palate), microcephaly, and hypoplastic phalanges/nails. * **Vitamin K Deficiency:** Phenytoin can also cause a deficiency of Vitamin K in the newborn, leading to coagulation defects. Prophylactic Vitamin K is often given to the mother in the last month of pregnancy. * **Management:** Pregnant women on phenytoin should receive high-dose folic acid (5 mg/day) to mitigate the risk of NTDs.
Question 6: Which of the following drugs are known to cause fetal renal anomalies?
- A. Frusemide
- B. Enalapril (Correct Answer)
- C. Angiotensin receptor blocker
- D. Amlodipine
Explanation: **Explanation:** The correct answer is **Enalapril** (and by extension, Angiotensin Receptor Blockers, though Enalapril is the classic prototype cited in this context). **1. Why Enalapril is Correct:** Enalapril is an **ACE Inhibitor (ACEI)**. ACEIs are strictly contraindicated in the 2nd and 3rd trimesters of pregnancy because they interfere with the fetal Renin-Angiotensin-Aldosterone System (RAAS). Fetal renal perfusion and development are highly dependent on Angiotensin II. Inhibition leads to **fetal renal dysgenesis**, which results in **oligohydramnios** (decreased amniotic fluid). This lack of fluid causes the "Oligohydramnios Sequence" (Potter’s sequence), characterized by pulmonary hypoplasia, limb contractures, and cranial ossification defects. **2. Analysis of Other Options:** * **Angiotensin Receptor Blockers (ARBs):** While ARBs also cause similar renal anomalies, **Enalapril** is the more frequently tested "classic" answer in NEET-PG for this specific complication. *Note: In many clinical scenarios, both B and C are considered fetotoxic; however, ACEIs have the longest-standing documented association with renal tubular dysgenesis.* * **Frusemide:** This is a loop diuretic. While generally avoided in pregnancy due to the risk of decreased placental perfusion, it is not a primary teratogen associated with structural renal anomalies. * **Amlodipine:** This is a Calcium Channel Blocker (CCB). CCBs are generally considered safe or have no proven teratogenic risk in humans; Nifedipine is actually frequently used to manage gestational hypertension. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Hypertension in Pregnancy:** Labetalol (followed by Methyldopa and Hydralazine). * **ACEI Teratogenicity:** Often referred to as **"ACEI Fetopathy."** * **Critical Window:** ACEIs are not typically structural teratogens in the *1st trimester* (though still avoided), but are lethal to the *fetal kidney* in the 2nd and 3rd trimesters. * **Key Triad:** Renal dysgenesis + Oligohydramnios + Hypocalvaria (skull defects).
Question 7: Which of the following medications is absolutely contraindicated for a mother who is breastfeeding her newborn baby?
- A. Amphetamines (Correct Answer)
- B. Carbamazepine
- C. Labetalol
- D. Ibuprofen
Explanation: **Explanation:** The safety of medications during breastfeeding depends on the drug's concentration in breast milk, its oral bioavailability in the infant, and its potential for toxicity. **1. Why Amphetamines are the Correct Answer:** Amphetamines (Option A) are **absolutely contraindicated** during breastfeeding. They are highly lipophilic and concentrate in breast milk at levels much higher than maternal plasma. In newborns, they can cause significant CNS stimulation, leading to irritability, agitation, poor sleeping patterns, tachycardia, and potential long-term neurodevelopmental issues. Furthermore, amphetamines can suppress maternal prolactin levels, potentially interfering with milk production. **2. Analysis of Incorrect Options:** * **Carbamazepine (Option B):** Considered "compatible" with breastfeeding by the AAP. While it does enter breast milk, the amounts are usually sub-clinical. Monitoring for infant jaundice or sedation is advised, but it is not a contraindication. * **Labetalol (Option C):** This is a preferred beta-blocker in lactation because it is highly protein-bound, resulting in very low concentrations in breast milk. * **Ibuprofen (Option D):** The NSAID of choice for breastfeeding mothers. It has extremely low excretion into milk and a short half-life, making it safe for the infant. **3. NEET-PG High-Yield Pearls:** * **Absolute Contraindications to Breastfeeding (Maternal Drugs):** Anticancer drugs (antimetabolites), Radioactive isotopes (e.g., Iodine-131), Lithium, Ergotamine, Retinoids, and Drugs of abuse (Cocaine, Amphetamines). * **Safe Alternatives:** If a mother needs an antibiotic, **Penicillins/Cephalosporins** are preferred over Tetracyclines. For analgesia, **Paracetamol/Ibuprofen** are preferred over Aspirin (due to Reye’s syndrome risk). * **Rule of Thumb:** Drugs with high molecular weight, high protein binding, and low lipid solubility are less likely to cross into breast milk.
Question 8: Which parameter is most important for determining drug dosage in a child?
- A. Weight (Correct Answer)
- B. Age
- C. Height
- D. Investigation results
Explanation: **Explanation:** **1. Why Weight is the Correct Answer:** In pediatric pharmacology, **Body Weight (kg)** is the most widely used and practical parameter for calculating drug dosages. This is because children undergo rapid physiological changes, and weight serves as a reliable proxy for the volume of distribution ($V_d$) and metabolic capacity. Most pediatric drug references (like the IPV or Nelson’s) provide dosages in **mg/kg/day**. While Body Surface Area (BSA) is technically the most accurate method for drugs with a narrow therapeutic index (like chemotherapy), weight remains the standard bedside parameter for general prescribing. **2. Why Other Options are Incorrect:** * **Age (B):** Age-based formulas (e.g., Young’s or Dilling’s rule) are largely obsolete. Age does not account for the significant variation in growth; two 5-year-olds can have vastly different weights, leading to potential under-dosing or toxicity. * **Height (C):** Height alone does not correlate well with the metabolic rate or the volume of distribution of most drugs. It is primarily used to calculate BSA or to assess growth milestones. * **Investigation Results (D):** While renal (creatinine) or hepatic function tests are crucial for *adjusting* doses in sick children, they are not the primary parameter for *determining* the initial baseline dose. **3. High-Yield Clinical Pearls for NEET-PG:** * **BSA Calculation:** The most accurate method for pediatric dosing is **Body Surface Area (BSA)**, calculated using the Mosteller formula: $\sqrt{\frac{Height(cm) \times Weight(kg)}{3600}}$. * **Clark’s Rule:** A classic (though less used) formula based on weight: $\text{Child Dose} = \frac{\text{Weight in lbs}}{150} \times \text{Adult Dose}$. * **Neonatal Caution:** In neonates, weight-based dosing must be adjusted for their higher total body water percentage and immature glucuronidation (e.g., risk of Gray Baby Syndrome with Chloramphenicol).
Question 9: The most common adverse effect particularly seen in young children because of the use of sodium valproate is:
- A. Hepatitis (Correct Answer)
- B. Loss of hair
- C. Anorexia
- D. Tremor
Explanation: **Explanation:** **Sodium Valproate** is a broad-spectrum antiepileptic drug, but its use in the pediatric population requires extreme caution due to the risk of **idiosyncratic hepatotoxicity** [1], [2]. 1. **Why Hepatitis is Correct:** The most serious and potentially fatal adverse effect of valproate is **fulminant hepatitis (Hepatotoxicity)**. This risk is significantly higher in children **under the age of 2 years**, especially those on polytherapy or those with underlying metabolic/mitochondrial disorders (e.g., POLG mutations). The mechanism involves the formation of toxic metabolites like 4-pentenoic acid, which interfere with mitochondrial fatty acid oxidation. 2. **Analysis of Incorrect Options:** * **Loss of hair (Alopecia):** This is a common side effect of valproate (often resulting in curly hair regrowth), but it is not life-threatening and is seen across all age groups, not specifically "particularly" concerning in young children compared to hepatitis. * **Anorexia:** While gastrointestinal upset is common, valproate more frequently causes **increased appetite and weight gain** rather than anorexia. * **Tremor:** This is a dose-related side effect typically seen in older children and adults on long-term therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** Valproate is highly teratogenic, causing **Neural Tube Defects** (Spina Bifida) by interfering with folate metabolism. * **Pancreatitis:** It is a known cause of acute hemorrhagic pancreatitis. * **Monitoring:** LFTs (Liver Function Tests) should be performed before and during the first 6 months of therapy. * **Other Side Effects (Mnemonic: VALPROATE):** **V**omiting, **A**lopecia, **L**iver toxicity, **P**ancreatitis/Platelets low, **R**etention of fat (Weight gain), **O**edema, **A**norexia (rarely), **T**remor/Teratogenicity, **E**ncephalopathy (Hyperammonemia).
Question 10: Gray baby syndrome is caused by which of the following drugs?
- A. Chlorpromazine
- B. Chloramphenicol (Correct Answer)
- C. Phenytoin
- D. Gentamycin
Explanation: **Explanation:** **Gray Baby Syndrome** is a serious and potentially fatal adverse reaction associated with the administration of **Chloramphenicol** in neonates (especially premature infants). **Why Chloramphenicol is the correct answer:** The syndrome occurs due to the physiological immaturity of the neonatal liver and kidneys. There are two primary mechanisms: 1. **Deficiency of Glucuronyl Transferase:** Neonates lack sufficient levels of this enzyme, which is required to conjugate chloramphenicol into its inactive form. 2. **Reduced Renal Excretion:** Immature kidneys cannot effectively excrete the unconjugated drug. This leads to toxic accumulation of the drug, causing mitochondrial injury. Clinical features include abdominal distension, vomiting, progressive cyanosis (giving the skin a characteristic **ash-gray color**), hypothermia, and cardiovascular collapse. **Why other options are incorrect:** * **Chlorpromazine:** An antipsychotic that can cause extrapyramidal symptoms or neonatal withdrawal if used during pregnancy, but not Gray Baby Syndrome. * **Phenytoin:** An antiepileptic known for **Fetal Hydantoin Syndrome** (cleft lip/palate, microcephaly) if taken during pregnancy, and gingival hyperplasia in children. * **Gentamycin:** An aminoglycoside primarily associated with **ototoxicity and nephrotoxicity** in all age groups. **High-Yield Clinical Pearls for NEET-PG:** * **Treatment:** Immediate discontinuation of the drug; exchange transfusion or charcoal hemoperfusion may be required. * **Other Chloramphenicol Side Effects:** Dose-dependent bone marrow suppression and idiosyncratic **Aplastic Anemia** (most serious). * **Drug of Choice:** Chloramphenicol remains a backup for Typhoid fever and H. influenzae meningitis in specific settings, but its use is strictly limited in neonates.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free